Introduction: Adipose tissue stromal cells contain a substantial number of mesenchymal stem cells. As such, their application to regeneration of miscellaneous impaired organs has attracted much attention. Methods: We designed a clinical study to investigate freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell (ADRC) therapy for liver cirrhosis and conducted treatment in four cirrhotic patients. ADRCs were isolated from autologous subcutaneous adipose tissue obtained by the liposuction method, followed with use of the Celution system adipose tissue dissociation device. The primary endpoint is assessment of safety one month after treatment. We also characterized the obtained ADRCs. Results: Two patients had type C cirrhosis, one had nonalcoholic steatohepatitis-cirrhosis, and one had type B cirrhosis. No serious adverse events were observed during the 1-month study period after freshly isolated ADRC infusion. Serum albumin concentrations were maintained or improved during this period as well as during the succeeding follow-up of approximately 1 year in two patients and 6 months in another patient. Liver regeneration-related factors, namely hepatocyte growth factor and interleukin-6, were elevated 1 day after ADRC treatment in all patients. The obtained freshly isolated ADRCs were expanded in culture and found to express mesenchymal stem cell markers. Gene expression profile analysis of ADRCs was shown to involve inflammatory features, suggesting that characteristics of the obtained ADRCs were related to immunomodulatory biological effects. Conclusion: This clinical study treatment for liver cirrhosis using ADRCs was proven to be safely conductible, and can be further investigated in future for regeneration/repair of liver cirrhosis.
Introduction
Liver cirrhosis is the end-stage condition of a variety of chronic liver diseases, including viral hepatitis, primary biliary cirrhosis, alcoholic hepatitis, and nonalcoholic steatohepatitis [1] . Liver transplantation is the ultimate treatment for hepatic failure, which is the end-stage of cirrhosis. Cirrhosis occurs when the fundamental cause of chronic liver disease is not radically eliminated or controlled, resulting in the persistence of hepatic inflammation [2] .
However, liver transplantation is associated with many problems because it is an invasive procedure. Moreover, there exists a lack of donors, especially in Japan, where living-donor liver transplantation is still mainly conducted [3] . Therefore, an alternative novel therapy for cirrhosis should be developed to prevent further disease progression, avoid hepatic failure requiring liver transplantation, and decrease the risk of hepatocellular carcinoma, which frequently occurs as a result of the advanced fibrosis of the liver and worsens the prognosis and quality of life of patients with cirrhosis.
Adipose tissue contains a substantial number of stem cells in its stromal fraction [4] . Mesenchymal stromal cells (MSCs) are somatic stem cells capable of differentiating into various types of cells [5] , including hepatocytes [6, 7] . In addition, they have strong immunomodulatory effects, which are principally beneficial for inflammation-related diseases in any organs [8, 9] . As such, much attention has been given to their application in regeneration therapy of various impaired organs. In a nonclinical study, we confirmed that adipose tissue-derived stromal cells are therapeutically beneficial in murine cirrhosis models because they improved hepatocyte function and ameliorated hepatic fibrosis and persistent inflammation [10] .
We designed and conducted a regenerative therapy clinical study using autologous freshly isolated adipose tissue-derived stromal/stem (regenerative) cells (ADRCs) for liver cirrhosis (UMIN000009122, NCT01062750). The freshly obtained cells were infused through a catheter, the tip of which was placed in the common hepatic artery, and the maximal number of cells administered was 6.6 Â 10 5 cells/kg. Four cirrhotic patients were treated. During the 1-month study period, no serious adverse effects were observed. Serum hepatocyte growth factor (HGF) and interleukin (IL)-6 levels were elevated 1 day after ADRC treatment in all patients. Serum concentrations of albumin in three of the four treated cirrhotic patients were improved after treatment during the study period as well as during follow-up. The obtained ADRCs did not merely contain lineagepotent cells, but were characterized to have immune-related biological functions by gene expression analysis. This clinical study investigating autologous freshly isolated ADRC treatment for liver cirrhosis was successful in demonstrating safety and its potential therapeutic efficacy.
Methods

Clinical study objectives
The primary aim of this clinical study was to confirm the safety of autologous ADRC therapy in cirrhotic patients (clinical research registration: ClinicalTrials.gov, registered number: NCT01062750, UMIN, registered number: UMIN000009122). Eligibility criteria included clinically diagnosed liver cirrhosis with relatively maintained hepatic function ( Table 1) . The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the Japanese Ministry of Health, Labour and Welfare and the institutional review board. The written informed consent was obtained from each patient, respectively. The study was conducted under monitoring by Innovative Clinical Research Center, Kanazawa University.
Autologous ADRC treatment and clinical assessment
Adipose tissue was obtained from the subcutaneum of the patients' abdomen or buttocks using the Tumescent liposuction method under general anesthesia [11, 12] . The obtained adipose tissue was put into the Celution adipose tissue dissociation system (Cytori Therapeutics Inc., San Diego, CA), which is investigational device digesting adipose tissue automatically under sterile conditions to isolate ADRCs [13] . Cell viability was confirmed using the NucleoCounter ® (Chemometec A/S, Allerod, Denmark) as well as with microscopic examination using the Trypan-blue dye exclusion test (SigmaeAldrich, St. Louis, MO). We prepared freshly isolated ADRCs aliquot which contained 1 Â 10 6 cells/ml suspended in lactate ringer liquid. We administered 3.3 Â 10 5 cells/kg and 6.6 Â 10 5 cells/kg of the freshly isolated ADRCs in two patients, respectively, using an intravascular catheter, which was subcutaneously inserted through the femoral artery and guided to the common hepatic artery. After confirmation of intrahepatic arterial flow into the liver with contrast reagent, the freshly isolated ADRCs were infused directly into the cirrhotic liver. Since ADRCs were freshly isolated without culture, infusion of ADRCs was conducted on the same day of liposuction. The patients were studied for 1 month following ADRC treatment, and the primary endpoints measured at the end of the study period included confirmation of clinical safety, a physical examination, and enhanced abdominal computed tomography. Additionally, blood samples for generally established clinical laboratory parameters, including relevant examination of liver function, and for RNA, using PAXgene ® RNA tubes (PreAnalytiX GmbH, Germany), were collected during the study and follow-up periods.
Serum concentration of cytokines and chemokines
Peripheral blood was collected prior to and after ADRC infusion. The serum was separated by centrifugation, and the concentrations of various serum cytokines and chemokines were measured using Bio-Plex Pro Human Cytokine Group I and Ⅱ ® (Bio-Rad, Tokyo, Japan). The following cytokines and chemokines were measured: interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70) , IL-13, IL-17, granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor, interferon-g, monocyte chemoattractant protein-1, macrophage inflammatory protein-1b, tumor necrosis factor-a, IL-1a, IL-2Ra, IL-3, IL-12, IL-16, IL-18, cutaneous T-cell attracting chemokine, HGF, interferon-a2, leukemia inhibitory factor, monocyte chemoattractant protein-3, macrophage-colony stimulating factor, macrophage migration inhibitory factor, monokine induced by gamma interferon, nerve growth factor-b, stem cell factor, stem cell growth factor-b, stromal cell-derived factor-1a, tumor necrosis factor -b, and tumor necrosis factor-related apoptosis-inducing ligand.
Culture and expansion of ADRCs
The fraction of the obtained freshly isolated ADRCs were cultured in dishes with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Carlsbad, CA) and 10 ng/ml human basic fibroblast growth factor (PeproTech, Inc., Rocky Hill, NJ) to obtain cultured adipose tissue-derived stromal cells (cADSCs). The size of the ADRCs and the expanded cADSCs were measured and calculated using ImageJ software (http://imagej.nih. gov/ij/).
FACS analysis of ADRCs and cADSCs
A fraction of the obtained freshly isolated ADRCs and expanded cADSCs were subjected to analysis for surface antigen expression using human MSC antibodies. They were analyzed by flow cytometry using BD Stemflow™ ( Immunohistochemical staining of cells that had differentiated into adipocytes, osteocytes, and chondrocytes was performed using anti-FABP-4, anti-osteocalcin, and anti-Aggrecan, antibodies, respectively, followed by staining with the NorthernLights™ 557-conjugated secondary antibody and 4 0 ,6-diamidino-2-phenylindole, in accordance with the manufacturer's instructions.
Gene expression analysis
RNA was isolated from ADRCs and cADSCs which were obtained from all 4 patients using the Micro RNA isolation kit ® (Agilent Technologies, Santa Clara, CA) as well as from the all 4 patients' blood obtained in the PAXgene ® RNA tubes (Qiagen, Hilden, Germany), in accordance with the manufacturers' instructions. Gene expression analysis using DNA microarray analysis was performed as previously reported [14] . Briefly, the isolated RNA was amplified, followed by labeling with Cy3 using the Quick Amp Labeling Kit ® (Agilent Technologies, Palo Alto, CA). The labeled target complementary RNA was mixed and hybridized using the Whole Human Genome 4 Â 44 K Microarray Kit ® (Agilent Technologies), and the slides were scanned using a microarray scanner (Model G2505B; Agilent Technologies). Gene expression analysis was performed using Biometric Research Branch array tools (National Cancer Institute, http://linus.nci.nih.gov/BRB-ArrayTools.html). Hierarchical clustering and class comparison analysis of gene expression were performed to identify differentially expressed genes. Biological processes and networks were analyzed using the MetaCore™ software suite (GeneGo, Carlsbad, CA).
Results
Freshly isolated autologous ADRC treatment in four cirrhotic patients
Following the designed clinical study protocol, we registered five cirrhotic patients, eventually excluding one patient who was proven to be non-cirrhotic ( Table 2 ). The etiologies of the four cirrhotic patients were as follows: two patients had type C cirrhosis, one had nonalcoholic steatohepatitis-cirrhosis, and one had type B cirrhosis. The viability of the obtained freshly isolated ADRCs in all four patients was >93.5%. Sterilization of the obtained cells was confirmed by the procedure in the Japanese Pharmacopoeia. The former and latter two patients received 3. 1D ) activity and clinical symptoms such as dyspnea or chest pain indicating lung embolisms. We did not observe occurrence of severe anemia requiring blood transfusion ( Fig. 1) or physical hematoma. The subcutaneous color change to be purple as a consequence of liposuction completely disappeared in all patients at the end of observation period, 1 month. No serious harmful adverse events were noted during the 1-month period after ADRC treatment (Table 2) . Serum albumin and prothrombin activities and laboratory examinations reflecting hepatic function, especially for cirrhosis, were assessed during the study period as well as during the follow-up period. The type C HI-01 patient maintained prothrombin activity and serum albumin concentrations for approximately 1 year ( Fig. 2A) , while the type C HI-03 patient maintained a prothrombin time and improved serum albumin concentrations for 1 year (Fig. 2B ). The patient with nonalcoholic steatohepatitiscirrhosis (HI-04) maintained prothrombin activity and albumin levels for approximately 6 months (Fig. 2C) , and the patient with type B cirrhosis (HI-05) had improved serum albumin concentrations during the follow-up observation (Fig. 2D) . Additionally, we examined how cytokine/chemokine concentrations were affected after ADRC treatment. Among the examined cytokine/chemokine panels, serum HGF and IL-6 concentrations were elevated in all four treated patients 1 day after ADRC treatment compared with the pretreatment levels (Fig. 3) . Moreover, serum M-colony stimulating factor, macrophage migration inhibitory factor, and IL-18 levels were also increased (Fig. 4) , suggesting that active immune-modulatory humoral factors and liver regeneration-related factors were involved in modulating treatment with ADRCs.
Surface antigen expression and lineagepotency of the obtained cells
We examined the size and surface marker expression of the freshly isolated ADRCs as well as the cADSCs (Fig. 5, Table 3 , Supplemental Fig. 2 ). The average diameter of the ADRCs was 5.47 mm (Fig. 5A and C) , whereas that of cADSCs was 13.21 mm (Fig. 4B and D) , indicating a 2.5-fold increase in size during culture. We observed that CD44 mesenchymal antigen expression was prominent in the freshly isolated ADRCs because it was present in approximately 10%e45% of the obtained ADRC population (Table 3 , Supplemental Fig. 2A ). We successfully cultured ADRCs to expand the typical spindle-shaped MSCs (Fig. 5) . CD44, CD105, and CD73, all of which are considered to be mesenchymal stem cell surface markers, were expressed in the cADSCs (Table 4 , Supplemental  Fig. 2B ). These findings suggest that the ADRCs contained the phenotypic populations of MSCs. To further confirm that the expanded cADSCs were as lineagepotent as MSCs, we attempted to differentiate the cADSCs into adipocyte, osteocyte, and chondrocyte. Using immunohistochemical staining and morphological appearance, the cADSCs were proven to be lineagepotent in the differentiation-conditioned culture media (Fig. 6 ).
Biological characteristics of ADRCs and cADSCs suggested by gene expression profile
To further characterize the biological characteristics of freshly isolated ADRCs and cADSCs, we performed gene expression analysis using DNA microarray. When we compared the gene expression of ADRCs with that of whole blood obtained using PAXgene ® tubes before ADRC treatment by unsupervised clustering analysis, two clusters representing peripheral blood and ADRC were formed using 14,334 filter-passed evaluable genes (Fig. 7A) . We identified 769 significantly up-regulated genes, up to 10-fold, in ADRCs compared with peripheral blood (p < 0.001). The biological characteristics of these involved a cytoskeleton development involving WNT signaling and signal transduction involving Notch signaling, suggesting that ADRC gene expression profiles involve a regenerative processes (Table 5) . Next, we compared the gene expression profile of ADRCs and cADSCs. Using 14,099 filter-passed evaluable genes, unsupervised clustering analysis for gene expression of ADRCs and cADSCs showed that two clusters were formed: a classifying ADRC cluster and a cADSC cluster. Thus, the ADRC expression profiles were similar irrespective of the cirrhosis etiology (Fig. 7B) . We identified 668 genes with up-regulated expression in ADRCs compared with cADSCs (p < 0.001, 10-fold expression difference). The biological processes of these genes mostly implicated a variety of immune response-related processes, such as antigen presenting cell-related inflammation, natural killer cells, T cells, and cytokine signaling (Table 6 ). We also identified 141 genes with up-regulated expression in cADSCs compared with ADRCs. The biological processes involving these included development, extracellular matrix remodeling, and WNT signaling, suggesting the involvement of tissue repair-related and regeneration-related processes (Table 7) . Taken together, these results demonstrate that freshly isolated ADRCs contain MSCs whose biological effects are related to tissue repair and remodeling as well as development.
Discussion
We conducted a clinical study investigating freshly isolated autologous ADRC therapy for cirrhotic patients. ADRCs were obtained from autologous subcutaneous adipose tissue. The freshly obtained ADRCs without any processing or manufacturing were infused through a catheter inserted subcutaneously and placed into the hepatic artery. During the 1-month study observation period after ADRC infusion, no serious adverse reactions related to the treatment were observed. The serum albumin level and prothrombin time were maintained or improved during certain periods of the study and follow-up.
In addition, we found elevated serum concentrations of the cytokines HGF and IL-6, as well as other immune-mediating and inflammation-related humoral mediators, in treated patients. HGF enhances the proliferation of liver progenitor cells [15] and has been previously used clinically for hepatic failure [16] . IL-6 is involved in liver regeneration [17] . Therefore, elevation of these two cytokines implies that ADRC treatment may have humoral factor-mediated impacts on regeneration. However, we did not examine the potential mechanisms underlying how infused ADRCs exerted therapeutic effects locally through these liver regeneration-related cytokines in patients with cirrhosis. Importantly, the alteration of these cytokines/chemokines as humoral mediators was transient. The importance of an indirect effect of MSCs on the treatment of liver disease models was previously reported [8] . Liposuction and infusion of ADRCs were conducted on the same day, therefore, it is yet to be fundamentally disclosed whether ADRCs administration rather than liposuction procedure contributed to elevation of HGF, cytokines and chemokines in sera. Furthermore, the significance of these alterations as well as the detailed biological therapeutic mechanism underlying these effects should be further examined in the context of regenerative therapy, if ADRCs administration was beneficial for liver regenerative therapy of cirrhosis.
It is important concern how ADRCs should be delivered to the liver. In non-clinical experiments using murine hepatitis model, we found that majority of the infused adipose-tissue derived stromal cells accumulated in the lung when cells were administered via the peripheral blood with a fraction of cells reached to the liver [8] . In non-clinical experiments using cirrhotic murine models, we observed that adipose-tissue derived stromal cells directly administered into the liver via the splenic-portal vein route, similar route to the direct delivery of cells to the liver via hepatic artery, resided in the cirrhotic murine liver for at least 2 weeks with the enhancement effect of albumin expression [10] . Thus, we administered ADRCs via the hepatic artery to avoid the off-target accumulation in the lung, expecting the administered ADRCs reached and remained in the cirrhotic liver. Although this clinical study primarily aimed to confirm the safety of freshly isolated ADRC treatment, characterization of the obtained cells was considered to be important. Thus, we assessed the obtained remaining ADRCs. In addition, since adipose tissuederived stromal cells substantially contain mesenchymal stem cells, we also tried to expand the remaining ADRCs in culture and assessed their biological characteristics of the expanded cells. ADRCs are known to be enriched in mesenchymal stem cells [18, 19] . Flow cytometry analysis of the obtained ADRCs in this study showed that a substantial number of ADRCs expressed CD44 mesenchymal surface antigens, although cells expressing other mesenchymal stem cell antigens, such as CD73, CD90, and CD105, were small and heterogeneous. ADRCs were successfully expanded in vitro, and a considerable proportion of the cADSCs expressed other mesenchymal stem cell surface antigens including CD105, CD90, and CD73 [20] , although heterogeneity of surface antigens expression including CD45 in cADSCs was still observed. Thus, versatility of adipose tissue derived stromal cells, both ADRCs and cADSCs, in the context of cell surface antigens, should be further investigated whether they are also functionally heterogeneous or identical. Despite this concern, when cADSCs were cultured in a medium supplemented with growth/differentiation factors for adipocytes, osteocytes, and chondrocytes, they differentiated into these specific cells lineages morphologically and expressed their specific antigens, suggesting that ADRCs definitely contain a substantial fraction of mesenchymal stem cells. It is also important finding that entire features of cADSCs expanded from those of ADRCs were different from the original ADRCs in the context of size (Fig. 4) , surface antigen expression (Tables 3 and 4 ) and gene expression profile (Fig. 7) . Therefore, the current clinical study is limited to assessment of safety using freshly isolated ADRCs for liver regenerative therapy.
Using gene expression analysis, the biological process features of ADRCs were shown to be related to development and regeneration when compared with the expression profile of peripheral blood, indicating that ADRCs may be potentially regenerative [13, 18] . Intriguingly, their prominent gene expression features included immunological processes involving a variety of immune-mediating cell types as well as immunological signal transduction when compared with the gene expression profile of cADSCs. Cirrhosis is a condition of chronic hepatitis and persistent intrahepatic inflammation that results in the development of fibrosis, hepatocyte dysfunction, and blood flow alterations [21] . Considering the unique biological characteristics of patient-derived autologous ADRCs, which, as disclosed in this study, contain substantial MSCs with immunomodulating effects, ADRCs may be ideal for the treatment of chronic liver diseases, including cirrhosis. Thus, ADRC therapy could be a potential alternative for the treatment of chronic liver diseases that are not eradicated or uncontrolled, resulting in the destruction of liver function and architecture.
Gene expression profile of ADRCs was suggestive of regeneration-related processes compared to that of peripheral blood gene expression, and mesenchymal stem cell marker, CD44, was substantially expressed in ADRCs. However, the number of cells expressing other mesenchymal antigens such as CD73, CD90, and CD105 were small and heterogeneous. Therefore, further studies are to be conducted to find out the specific subpopulation in ADRCs, which is the most contributable to liver regeneration.
Utilization of freshly isolated ADRCs is beneficial because it avoids the need to manufacture cells. Similarly, clinical studies using freshly isolated cells from bone marrow without any manufacturing have been reported for therapy of liver cirrhosis [22] . Adipose tissue and bone marrow are known to contain MSCs [23] and are obtainable from a patient's own tissues; thus, both are attracting much attention in the context of practical implementation. Conducting further clinical trials investigating these cells, which are potentially beneficial for the regeneration of Immune response_Antigen presentation impaired organs, is extremely important to provide potential therapeutic beneficial properties. In addition, we could not assess how many cells were the most appropriate for obtaining sufficient therapeutic effect, since the current study was aimed to assess safety of the ADRC regenerative therapy enrolling and treating 4 patients. The future studies should also elucidate how frequent or many times ADRCs should be administered, leading to enhanced development of novel treatments for liver cirrhosis as well as other diseases [24] .
Conclusion
We conducted a clinical study investigating regenerative therapy for liver cirrhosis using intrahepatic arterial administration of freshly isolated autologous ADRCs. Further clinical trials are warranted to elucidate the potential therapeutic effects of ADRCs and to shed light on the important properties of mesenchymal stem cells on liver diseases.
